Loading the session
Loading the session
Loading instrument
$85.87
−2.94%Delayed · Pre-marketDelayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 06:26 IST · A quote does not mean the product is available to trade on your account.
Opens 8:00 pm IST
Opens 8:00 pm IST
Opens 8:00 pm IST
In brief
Questions investors ask
Quotes run fifteen minutes behind.
1 month: +34.6% (SPY −1.6%, XLV +13.5%). 3 months: +88.7% (SPY −0.4%, XLV +15.5%). 1 year: +491.3% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: CDNA, SPY and XLV · as of 4 Nov 2026
Closed at $85.86 on 4 Nov 2026: 5.5% below the 52-week high of $90.87 (30 Oct 2026) and 488.9% above the low of $14.58 (6 Nov 2025).
Daily price bars, split-adjusted · as of 4 Nov 2026
6.7M shares were sold short at the 15 Oct 2026 settlement, 12.8% of the 52.5M shares outstanding; covering them would take 4.5 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
The 4 Nov 2026 close of $85.86 was 38.0% above its 50-day average ($62.20) and 147.9% above its 200-day average ($34.64). It has closed above the 200-day for 144 sessions, since 13 Apr 2026. The 50-day average crossed above the 200-day on 16 Dec 2025, 222 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
The 14-session relative strength index closed at 73.8 on 4 Nov 2026, its 4th session at 70 or above. By convention a reading of 70 or above is called overbought and 30 or below oversold.
Daily closes, split-adjusted; Wilder's 14-session RSI · as of 4 Nov 2026
Price return, split-adjusted
At the 4 Nov 2026 close
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
July 16, 2026
+35.60%July 17, 2025
−38.49%May 10, 2024
+34.09%